关键词: 乳腺癌, 新辅助化疗, 蓝染示踪法, 前哨淋巴结活检

Abstract: 【Abstract】〓Objective〓To assess the feasibility of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) in breast cancer patients. Methods〓Sixty-nine patients with breast cancer were subjected to pre-operative NAC from 2012-01-01 to 2015-06-30 in Liuzhou Worker's hospital, and their clinical data of sentinel lymph node biopsy (SLNB) from axillary lymph node dissection (ALND) were analyzed. SLN identification rates and false negative rate of the patients were assessed. Results〓The identification rate for SLNB was 85.5%. The false-negative rate was 18.2%. Grouping the patients according to axillary lymph node (ALN) state before treatment, the size of the tumor,.location of the tumor,.the age of the patients and the injection site of blue dye,.the identification rates of ALN (-) group and ALN(+) group were 96.7% and 76.9% (P=0.049) respectively,.and had nothing to do with the left factors mentioned above. There was no statistical difference of the false-negative rate in different states of all the factors. Conclusion〓SLNB by blue dye trace method is feasible in ALN (-) breast cancer patients who have received NAC, while there are some risks for ALN (+) patients. Increasing the number of SLN might elevate the reliability of SLNB in patients after NAC.

Key words: Breast cancer, Sentinel lymph node biopsy, Blue dye trace method, Neoadjuvant chemotherapy